Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00134186 · ClinicalTrials.gov registry record · Phase 2

Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer

A Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms, sponsored by Pharmacyclics.

Completed
Registry status
Phase 2
Development phase
43
Enrollment target
1
Study location

NCT00134186 is a Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 43 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00134186, a Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 2
Development phase
43 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

Conditions Studied

Carcinoma, Renal Cell Urogenital Neoplasms Kidney Neoplasms Urologic Neoplasms

Interventions

  • DRUG motexafin gadolinium

Study Locations (1)

Texas

  • Methodist Hospital - Houston

Trial Details

FieldValue
Enrollment Target 43 participants
Phase Phase 2

Sponsor

Pharmacyclics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00134186

The ClinicalTrials.gov registry entry for NCT00134186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which motexafin gadolinium is the first listed.

NCT00134186 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00134186 about?

NCT00134186 is a clinical study titled "Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer". The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).

What is the current status of trial NCT00134186?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants.

What conditions does trial NCT00134186 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell, Urogenital Neoplasms, Kidney Neoplasms, Urologic Neoplasms.

What interventions are being tested in trial NCT00134186?

The interventions under investigation include: motexafin gadolinium (DRUG).

Who is sponsoring clinical trial NCT00134186?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00134186 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

Urogenital Neoplasms

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.